New FAQ offers practical framework for feline hyperesthesia
Bottom line
Feline hyperesthesia syndrome remains a diagnosis of exclusion, and a new peer-reviewed FAQ in Today’s Veterinary Practice aims to give general practitioners a more practical framework for working these cases. In the September 1, 2026 article, veterinary behaviorist Alison Gerken, DVM, DACVB, describes feline hyperesthesia syndrome, or FHS, as an episodic syndrome marked by skin rippling, agitation, and self-directed grooming or biting, but stresses that dermatologic disease, pain, seizures, and neurobehavioral factors can all contribute. The article’s key shift is away from treating FHS as a single disorder and toward targeted diagnostics, therapeutic trials, and multimodal management. (todaysveterinarypractice.com)
Why it matters: For veterinary professionals, the piece reinforces that FHS shouldn’t be diagnosed from one dramatic sign alone. Gerken recommends ruling out inflammatory skin disease, neuropathic or musculoskeletal pain, anal sac or tail pain, gastrointestinal contributors, and focal seizures before concluding the problem is primarily behavioral. Suggested first-line trials include NSAIDs, prednisolone, oclacitinib or an elimination diet, and levetiracetam when seizure activity is suspected, with longer-term options such as gabapentin, pregabalin, venlafaxine, fluoxetine, or other psychotropic support depending on the cat’s clinical phenotype. That approach lines up with outside sources from Cornell and recent literature pointing to FHS as a crossroads condition involving pain, neurology, dermatology, and behavior, rather than a tidy standalone diagnosis. (todaysveterinarypractice.com)
What to watch: Expect more discussion around phenotype-based treatment, especially as newer data on long-term outcomes and neuropathic pain management continue to shape how clinicians triage suspected FHS cases. (academic.oup.com)
Key facts
- Topic
- Feline hyperesthesia syndrome, or FHS
- Publication
- Today’s Veterinary Practice
- Publication date
- September 1, 2026
- Author
- Alison Gerken, DVM, DACVB
- Core framing
- Diagnosis of exclusion
- Common signs
- Skin rippling, agitation, self-directed grooming, or biting
- Recommended workup
- History, client video, and physical, dermatologic, orthopedic, and neurologic exams
- Key rule-outs
- Inflammatory skin disease, pain, seizures, anal sac or tail pain, gastrointestinal contributors, and focal seizures
- Treatment approach
- Targeted diagnostics, therapeutic trials, and multimodal management
A new peer-reviewed FAQ in Today’s Veterinary Practice is putting a practical clinical frame around one of feline medicine’s more frustrating syndromes: feline hyperesthesia syndrome. Published September 1, 2026, the article by Alison Gerken, DVM, DACVB, says FHS should be approached as a diagnosis of exclusion, not a reflex label for cats with skin rippling, agitation, or sudden self-directed biting and grooming. (todaysveterinarypractice.com)
That framing matters because FHS has long been difficult to pin down. Earlier reviews and reference sources have described the syndrome as poorly understood, with competing theories involving seizure activity, compulsive behavior, neuropathic pain, spinal disease, and stress-related arousal. Cornell’s feline health guidance similarly notes that clinicians still debate whether some cases are seizure-like, behavioral, pain-related, or secondary to another identifiable disorder, and emphasizes ruling out treatable causes first. (academic.oup.com)
Gerken’s article reflects that uncertainty, but turns it into a workflow for practice. The piece says many signs commonly associated with FHS can also be seen in healthy cats, so no single exam finding should make the diagnosis. Instead, the recommended workup starts with a detailed history, client video when available, and full physical, dermatologic, orthopedic, and neurologic examinations. Depending on presentation, that may extend to ectoparasite control, skin cytology, fungal testing, trichography, anal sac evaluation, CBC, chemistry, thyroid testing, urinalysis, FeLV/FIV testing, fecal antigen testing, radiography, and in more severe or refractory cases, advanced imaging or cerebrospinal fluid analysis. (todaysveterinarypractice.com)
The article also lays out a tiered treatment strategy tied to the leading differential. If musculoskeletal pain is suspected, NSAID trials are a reasonable start; if pruritus or inflammatory skin disease is more likely, prednisolone, oclacitinib, or an elimination diet may be appropriate; and if episodes are stereotyped or suggest focal seizures, levetiracetam can be considered even before a definitive epilepsy diagnosis is secured. For longer-term management, Gerken highlights gabapentin and pregabalin for suspected neuropathic pain or sensory dysregulation, and positions venlafaxine, SSRIs, tricyclics, or adjunctive lorazepam as options based on the cat’s phenotype and overlap between pain, anxiety, arousal, and compulsive behavior. (todaysveterinarypractice.com)
Recent literature gives some support to that more individualized approach. A 2025 retrospective case series of 28 cats with hyperesthesia syndrome found that 82% achieved an episode-free period of at least 9 months, and 93% had no clinical signs at 1-year follow-up across medical, behavioral, or combined treatment strategies. In that study, cats treated with fluoxetine alone had a median recovery time of 8 days and a 94% rate of episode-free periods of at least 9 months, though half of all cats remained on pharmacotherapy at one year. (academic.oup.com)
There’s also emerging case-level evidence that triggers and comorbid behavior can shape these presentations. A 2024 Vet Record Case Reports paper described scent-triggered hyperesthesia episodes and discussed frustration and environmental stress as possible contributors in at least one cat, alongside partial benefit from gabapentin and behavior modification. That doesn’t settle the etiology debate, but it does reinforce the idea that some cases may need both medical and environmental intervention. (pure.ed.ac.uk)
Why it matters: For veterinary teams, the biggest takeaway is that FHS may be less a singular diagnosis than a clinical pattern with multiple possible drivers. That has direct implications for case workup, client communication, and expectations. Pet parents may arrive after seeing dramatic online videos or after being told their cat has “twitchy cat syndrome,” but the more useful conversation is often about ruling out pain, skin disease, seizure disorders, and stress-related contributors in a structured way. Gerken’s article also sets a realistic treatment goal: better control of episode frequency, severity, and self-trauma, rather than promising a cure. (todaysveterinarypractice.com)
What to watch: The next development to follow is whether additional prospective studies can sort FHS cases into clearer phenotypes, especially pain-dominant, seizure-like, and anxiety- or compulsivity-linked presentations, which could make treatment selection less empirical and improve counseling around long-term management. (academic.oup.com)